Papers/PMID:25028535
Quetiapine for acute bipolar depression: a systematic review and meta-analysis.
Drug design, development and therapy2014The record
3 findings · 1 compound · 3 endpoints · 1 null
What it reported
How to read these marksWhat moved
2 findings
quetiapine — increases antidepressant treatment response rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The overall response rate, defined as ≥50% reduction on the depression rating scale scores, was higher in the quetiapine group at the end of the studies (RR 1.31, 95% CI 1.23 to 1.40; number needed to treat [NNT] 6, 95% CI 5 to 8).”
Quoted verbatim from Quetiapine for acute bipolar depression: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 150-600 mg/day
- Population
- Adults and children/adolescents with acute bipolar I or II depression; pooled RCTs of quetiapine versus placebo, end of studies
Effect 1.31 risk ratio, 95% CI 1.23 to 1.4
Quetiapine for acute bipolar depression: a systematic review and meta-analysis.2014PMID:25028535Permalink
quetiapine — increases withdrawal due to adverse events
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“While dropouts due to inefficacy were significantly lower in the quetiapine group (RR 0.31, 95% CI 0.19 to 0.53), dropouts due to adverse events were significantly higher in the quetiapine group (RR 1.88, 95% CI 1.20 to 2.96).”
Quoted verbatim from Quetiapine for acute bipolar depression: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 150-600 mg/day
- Population
- Adults and children/adolescents with acute bipolar I or II depression; pooled 11 short-term RCTs of quetiapine versus placebo
Effect 1.88 risk ratio, 95% CI 1.2 to 2.96
Quetiapine for acute bipolar depression: a systematic review and meta-analysis.2014PMID:25028535Permalink
What did not
1 finding
quetiapine — no detected effect on serious adverse event incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Moreover, there was no significant difference between quetiapine and placebo in the likelihood of having at least one serious adverse event (RR 0.85, 95% CI 0.49 to 1.48).”
Quoted verbatim from Quetiapine for acute bipolar depression: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 150-600 mg/day
- Population
- Adults and children/adolescents with acute bipolar I or II depression; pooled RCTs of quetiapine versus placebo
Effect 0.85 risk ratio, 95% CI 0.49 to 1.48
Quetiapine for acute bipolar depression: a systematic review and meta-analysis.2014PMID:25028535Permalink